Tabelecleucel
- Generic Name
- Tabelecleucel
- Brand Names
- Ebvallo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- G3NJ7M8N4H
- Background
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers. When given to a patient wit...
- Associated Conditions
- -
- Associated Therapies
- -
Major T Cell Trial in Solid Tumors Marks New Era
The VANCE trial, a multinational phase III study led by Singapore, concludes that T cell therapy for solid tumours is safe but requires refinement to improve outcomes. The trial, published in Annals on Oncology, involved 330 patients across 23 sites, showing no overall survival benefit but potential in specific subgroups. Future efforts aim to identify biomarkers for personalized T cell therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath